{"entity":{"id":"nct06697184","kind":"trial","name":"A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.","aka":[],"tldr":"A phase 1/2 trial of Sonrotoclax, Zanubrutinib in mantle cell lymphoma, run by BeOne Medicines, now recruiting.","summary":"A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. is a phase 1/2 interventional study registered as NCT06697184 by BeOne Medicines, with 258 participants planned, started 2025-01-23 and due to reach its primary completion in 2029-11-30. Interventions recorded: Sonrotoclax, Zanubrutinib. Conditions listed: Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06697184","url":"https://clinicaltrials.gov/study/NCT06697184"}],"tags":["ctgov-ingest"],"related":[],"cancers":["mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["sonrotoclax","zanubrutinib"],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06697184","phase":"1/2","setting":"A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule(s) in Adult Patients With Hematological Malignancies.","sponsor":"BeOne Medicines","enrolled":258,"outcomes":[]},"route":"/trials/nct06697184/","neighbours":{"cancer":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"}],"drug":[{"id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/"},{"id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}]}}